JiXing is a leading biotechnology company committed to bringing innovative science and medicines to underserved patients in China.
The need
We formed JiXing in early 2020, borne out of a two-year study of innovation, biotechnology, and access to healthcare in China. JIXING is a leading biotechnology company headquartered in Shanghai committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
The mission
Backed by RTW, JiXing partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, JiXing is dedicated to delivering a meaningful and lasting impact on patients in Greater China.
Our progress
JiXing’s pipeline now includes 7 assets focused on cardiovascular and ophthalmology conditions with high unmet need through partnerships with Cytokinetics, Milestone, LENZ Therapeutics, and Oyster Pharma. RTW further capitalized JiXing by providing a Series B and C funding.
